<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37308302</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Global Prevalence and Incidence of Amyotrophic Lateral Sclerosis: A Systematic Review.</ArticleTitle><Pagination><StartPage>e613</StartPage><EndPage>e623</EndPage><MedlinePgn>e613-e623</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000207474</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder affecting upper and lower motor neurons. Due to its rarity and rapidly progressive nature, studying the epidemiology of ALS is challenging, and a comprehensive picture of the global burden of this disease is lacking. The objective of this systematic review was to describe the global incidence and prevalence of ALS.</AbstractText><AbstractText Label="METHODS">We searched MEDLINE, Embase, Global Health, PsycInfo, Cochrane Library, and CINAHL to identify articles published between January 1, 2010, and May 6, 2021. Studies that were population based and reported estimates of prevalence, incidence, and/or mortality of ALS were eligible for inclusion. This study focuses on the incidence and prevalence. Quality assessment was performed using a tool developed to evaluate methodology relevant to prevalence and incidence studies. This review was registered with PROSPERO, CRD42021250559.</AbstractText><AbstractText Label="RESULTS">This search generated 6,238 articles, of which 140 were selected for data extraction and quality assessment. Of these, 85 articles reported on the incidence and 61 on the prevalence of ALS. Incidence ranged from 0.26 per 100,000 person-years in Ecuador to 23.46 per 100,000 person-years in Japan. Point prevalence ranged from 1.57 per 100,000 in Iran to 11.80 per 100,000 in the United States. Many articles identified cases with ALS from multiple data sources.</AbstractText><AbstractText Label="DISCUSSION">There is variation in reported incidence and prevalence estimates of ALS across the world. While registries are an important and powerful tool to quantify disease burden, such resources are not available everywhere. This results in gaps in reporting of the global epidemiology of ALS, as highlighted by the degree of variation (and quality) in estimates of incidence and prevalence reported in this review.</AbstractText><CopyrightInformation>&#xa9; 2023 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolfson</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Neuroepidemiology Research Unit (C.W., D.E.G.), Research Institute of the McGill University Health Centre; Department of Medicine (C.W.), Faculty of Medicine and Health Sciences, Department of Epidemiology (C.W., F.I.), Biostatistics and Occupational Health, School of Population and Global Health, and Department of Pediatrics (M.O.), Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. christina.wolfson@mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauvin</LastName><ForeName>Danielle E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>From the Neuroepidemiology Research Unit (C.W., D.E.G.), Research Institute of the McGill University Health Centre; Department of Medicine (C.W.), Faculty of Medicine and Health Sciences, Department of Epidemiology (C.W., F.I.), Biostatistics and Occupational Health, School of Population and Global Health, and Department of Pediatrics (M.O.), Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishola</LastName><ForeName>Foluso</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Neuroepidemiology Research Unit (C.W., D.E.G.), Research Institute of the McGill University Health Centre; Department of Medicine (C.W.), Faculty of Medicine and Health Sciences, Department of Epidemiology (C.W., F.I.), Biostatistics and Occupational Health, School of Population and Global Health, and Department of Pediatrics (M.O.), Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskoui</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Neuroepidemiology Research Unit (C.W., D.E.G.), Research Institute of the McGill University Health Centre; Department of Medicine (C.W.), Faculty of Medicine and Health Sciences, Department of Epidemiology (C.W., F.I.), Biostatistics and Occupational Health, School of Population and Global Health, and Department of Pediatrics (M.O.), Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009656" MajorTopicYN="N" Type="Geographic">North America</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013020" MajorTopicYN="N" Type="Geographic">South America</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044349" MajorTopicYN="N" Type="Geographic">Oceania</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>21</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37308302</ArticleId><ArticleId IdType="pmc">PMC10424837</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000207474</ArticleId><ArticleId IdType="pii">WNL.0000000000207474</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. In: Araki T, ed. Amyotrophic Lateral Sclerosis. Exon Publications; 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34473440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennum P, Ibsen R, Pedersen SW, Kjellberg J. Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J Neurol. 2013;260(3):785-793.</Citation><ArticleIdList><ArticleId IdType="pubmed">23104122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. . Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118-130. doi:10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, et al. . Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46(1):57-74. doi:10.1093/ije/dyw061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, et al. . Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944-953. doi:10.1007/s00415-019-09652-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lekoubou A, Echouffo-Tcheugui JB, Kengne AP. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review. BMC Public Health. 2014;14:653. doi:10.1186/1471-2458-14-653</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-653</ArticleId><ArticleId IdType="pmc">PMC4094534</ArticleId><ArticleId IdType="pubmed">24969686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingwell E, Marriott JJ, Jett&#xe9; N, et al. . Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13(1):128. doi:10.1186/1471-2377-13-128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-128</ArticleId><ArticleId IdType="pmc">PMC3856596</ArticleId><ArticleId IdType="pubmed">24070256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson C, Kilborn S, Oskoui M, Genge A. Incidence and prevalence of amyotrophic lateral sclerosis in Canada: a systematic review of the literature. Neuroepidemiology. 2009;33(2):79-88. doi:10.1159/000222089</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000222089</ArticleId><ArticleId IdType="pubmed">19494548</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle MH. Guidelines for evaluating prevalence studies. Evidence Based Ment Health. 1998;1(2):37-39. doi:10.1136/ebmh.1.2.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ebmh.1.2.37</ArticleId></ArticleIdList></Reference><Reference><Citation>Covidence systematic review software. covidence.org.</Citation></Reference><Reference><Citation>United Nations Department of Economic and Social Affairs, Statistics Division. Accessed June 1, 2021. unstats.un.org/unsd/methodology/m49/.</Citation></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. R-project.org/.</Citation></Reference><Reference><Citation>Henning F, Heckmann JM, Naidu K, Vlok L, Cross HM, Marin B. Incidence of motor neuron disease/amyotrophic lateral sclerosis in South Africa: a 4-year prospective study. Eur J Neurol. 2021;28(1):81-89.</Citation><ArticleIdList><ArticleId IdType="pubmed">32888367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajjadi M, Etemadifar M, Nemati A, et al. . Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran. Eur J Neurol. 2010;17(7):984-989.</Citation><ArticleIdList><ArticleId IdType="pubmed">20214678</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi Y, Atsuta N, Sobue G, Morita M, Nakano I. Prevalence and incidence of amyotrophic lateral sclerosis in Japan. J Epidemiol. 2014;24(6):494-499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213224</ArticleId><ArticleId IdType="pubmed">25373461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kihira T, Yoshida S, Kondo T, et al. . An increase in ALS incidence on the Kii Peninsula, 1960-2009: a possible link to change in drinking water source. Amyotroph Lateral Scler. 2012;13(4):347-350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409458</ArticleId><ArticleId IdType="pubmed">22632441</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil C, Zach N, Rishoni S, Shalev V, Chodick G. Epidemiology of amyotrophic lateral sclerosis: a population-based study in Israel. Neuroepidemiology. 2016;47(2):76-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumiya K, Wada T, Fujisawa M, et al. . Amyotrophic lateral sclerosis and parkinsonism in Papua, Indonesia: 2001-2012 survey results. BMJ Open. 2014;4(4):e004353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996815</ArticleId><ArticleId IdType="pubmed">24740977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansukhani KA, Barretto MA, Donde SA, Wandrekar J, Nigudkar A, Nair R. Epidemiological survey of neurological diseases in a tribal population cluster in Gujarat. Ann Indian Acad Neurol. 2018;21(4):294-299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6238552</ArticleId><ArticleId IdType="pubmed">30532360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Wang KC, Hwang CS, Lee IT, Lee CT. Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999-2008. J Formos Med Assoc. 2015;114(7):612-619.</Citation><ArticleIdList><ArticleId IdType="pubmed">26154753</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun KY, Park J, Oh KW, et al. . Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry. 2019;90(4):395-403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581156</ArticleId><ArticleId IdType="pubmed">30409890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JM, Park JH, Kim HS, et al. . Epidemiology and diagnostic process of amyotrophic lateral sclerosis as distinct from myelopathy: 5-year cohort study of whole-population in South Korea. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7-8):547-554.</Citation><ArticleIdList><ArticleId IdType="pubmed">30421999</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevic Z, Kostic-Dedic S, Peric S, et al. . Prognostic factors and survival of ALS patients from Belgrade, Serbia. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7-8):508-514.</Citation><ArticleIdList><ArticleId IdType="pubmed">27315438</ArticleId></ArticleIdList></Reference><Reference><Citation>Seals RM, Hansen J, Gredal O, Weisskopf MG. Age-period-cohort analysis of trends in amyotrophic lateral sclerosis in Denmark, 1970-2009. Am J Epidemiol. 2013;178(8):1265-1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792730</ArticleId><ArticleId IdType="pubmed">24064744</ArticleId></ArticleIdList></Reference><Reference><Citation>Giagheddu M, Puggioni G, Tacconi P, et al. . Amyotrophic lateral sclerosis in Sardinia (Italy): epidemiologic features from 1957 to 2000. Acta Neurol Scand. 2013;127(4):251-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">22881448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandettini di Poggio M, Sormani MP, Truffelli R, et al. . Clinical epidemiology of ALS in Liguria, Italy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(1):52-57.</Citation><ArticleIdList><ArticleId IdType="pubmed">23030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Brylev L, Ataulina A, Fominykh V, et al. . The epidemiology of amyotrophic lateral sclerosis in Moscow (Russia). Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5-6):410-415.</Citation><ArticleIdList><ArticleId IdType="pubmed">32476476</ArticleId></ArticleIdList></Reference><Reference><Citation>Demetriou CA, Hadjivasiliou PM, Kleopa KA, et al. . Epidemiology of amyotrophic lateral sclerosis in the Republic of Cyprus: a 25-year retrospective study. Neuroepidemiology. 2017;48(1-2):79-85.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528330</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton DJ, Newton J, Stephenson LJ, et al. . Changing epidemiology of motor neurone disease in Scotland. J Neurol. 2019;266(4):817-825.</Citation><ArticleIdList><ArticleId IdType="pubmed">30805795</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, Rath J, Fuzi J, et al. . Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology. 2015;44(1):6-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25571962</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg R, Farrugia Wismayer M, Bonavia K, et al. . Genetic analysis of ALS cases in the isolated island population of Malta. Eur J Hum Genet. 2021;29(4):604-614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8115635</ArticleId><ArticleId IdType="pubmed">33414559</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliatti M, Parish LD, Cossu P, et al. . Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995-2009. J Neurol. 2013;260(2):572-579.</Citation><ArticleIdList><ArticleId IdType="pubmed">23052600</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose L, McKim D, Leasa D, et al. . Trends in incidence, prevalence, and mortality of neuromuscular disease in Ontario, Canada: a population-based retrospective cohort study (2003-2014). PLoS One. 2019;14(3):e0210574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435115</ArticleId><ArticleId IdType="pubmed">30913206</ArticleId></ArticleIdList></Reference><Reference><Citation>Golby R, Poirier B, Fabros M, Cragg JJ, Yousefi M, Cashman N. Five-year incidence of amyotrophic lateral sclerosis in British Columbia (2010-2015). Can J Neurol Sci. 2016;43(6):791-795.</Citation><ArticleIdList><ArticleId IdType="pubmed">27476760</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Mehal JM, Holman RC, Rowland LP, Rowland AS, Cheek JE. Incidence of amyotrophic lateral sclerosis among American Indians and Alaska natives. JAMA Neurol. 2013;70(4):476-480.</Citation><ArticleIdList><ArticleId IdType="pubmed">23440294</ArticleId></ArticleIdList></Reference><Reference><Citation>Caller TA, Andrews A, Field NC, Henegan PL, Stommel EW. The epidemiology of amyotrophic lateral sclerosis in New Hampshire, USA, 2004-2007. Neurodegener Dis. 2015;15(4):202-206.</Citation><ArticleIdList><ArticleId IdType="pubmed">25896575</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper CJ, Sorenson EJ, Mandrekar J. Epidemiology of amyotrophic lateral sclerosis in Minnesota: a year-long population based study. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):520-523.</Citation><ArticleIdList><ArticleId IdType="pubmed">26083871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannuzel A, Mecharles S, Tressieres B, et al. . Clinical varieties and epidemiological aspects of amyotrophic lateral sclerosis in the Caribbean island of Guadeloupe: a new focus of ALS associated with Parkinsonism. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):216-223.</Citation><ArticleIdList><ArticleId IdType="pubmed">25646866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya R, Harvey RA, Abraham K, Rosen J, Mehta P. Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):251-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">30892090</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, Topol B, Kaye W, et al. . Estimation of the prevalence of amyotrophic lateral sclerosis in the United States using National Administrative Healthcare Data from 2002 to 2004 and capture-recapture methodology. Neuroepidemiology. 2018;51(3-4):149-157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250049</ArticleId><ArticleId IdType="pubmed">30092573</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani R, Wagner L, Horton K, Kaye W. Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1-2):123-130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130365</ArticleId><ArticleId IdType="pubmed">31795746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucheli M, Andino A, Montalvo M, et al. . Amyotrophic lateral sclerosis: analysis of ALS cases in a predominantly admixed population of Ecuador. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1-2):106-113.</Citation><ArticleIdList><ArticleId IdType="pubmed">24245684</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapata-Zapata CH, Franco Dager E, Aguirre-Acevedo DC, de Carvalho M, Solano-Atehortua J. Prevalence, incidence, and clinical-epidemiological characterization of amyotrophic lateral sclerosis in Antioquia: Colombia. Neuroepidemiology. 2020;54(3):251-257.</Citation><ArticleIdList><ArticleId IdType="pubmed">31812965</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettini M, Vicens J, Giunta DH, Rugiero M, Cristiano E. Incidence and prevalence of amyotrophic lateral sclerosis in an HMO of Buenos Aires, Argentina. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7-8):598-603.</Citation><ArticleIdList><ArticleId IdType="pubmed">23834086</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden-Junior E, Becker J, Schestatsky P, Rotta FT, Marrone CD, Gomes I. Prevalence of amyotrophic lateral sclerosis in the city of Porto Alegre, in Southern Brazil. Arq Neuropsiquiatr. 2013;71(12):959-962.</Citation><ArticleIdList><ArticleId IdType="pubmed">24347016</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulfield A, Cariga P. Incidence of motor neurone disease within MidCentral Region, New Zealand. NZ Med J. 2018;131(1485):48-51.</Citation><ArticleIdList><ArticleId IdType="pubmed">30408817</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuschl G, Beghi E, Fazekas F, et al. . The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):e551-e567.</Citation><ArticleIdList><ArticleId IdType="pubmed">33007212</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M, Marin B, et al. . Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1083-1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T, Abajobir AA, Abbafati C, et al. . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5605509</ArticleId><ArticleId IdType="pubmed">28919117</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbastabar H, Bitarafan S, Harirchian MH. The trend of incidence and burden of neurological disease in Iran between 1990 and 2017: based on global burden of disease estimations. Iran J Neurol. 2019;18(3):134-142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858595</ArticleId><ArticleId IdType="pubmed">31749935</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD US Neurological Disorders Collaborators, Feigin VL, Vos T, et al. . Burden of neurological disorders across the US from 1990-2017: a Global Burden of Disease Study. JAMA Neurol. 2021;78(2):165-176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7607495</ArticleId><ArticleId IdType="pubmed">33136137</ArticleId></ArticleIdList></Reference><Reference><Citation>Access eReferences at</Citation></Reference><Reference><Citation>links.lww.com/WNL/C897.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>